Scarica l'app Stockscreener
32.35
0.62%
0.20
Dopo l'orario di chiusura:
32.00
-0.35
-1.08%
Eton Pharmaceuticals Inc Borsa (ETON) Ultime notizie
Eton Pharmaceuticals (ETON) surges 19.8%: Is this an indication of further gains? - MSN
Eton Pharmaceuticals (ETON) Surges 4.75% as Momentum Builds Toward ResistanceWatchlist Stock Ideas - newsline.com
Trading the Move, Not the Narrative: (ETON) Edition - Stock Traders Daily
Eton Pharmaceuticals (NASDAQ: ETON) 2026 vote supports board and auditor - Stock Titan
Eton Pharmaceuticals (ETON) Gains 2.8% as Bullish Momentum Builds Toward ResistanceHigh Beta Stocks - newsline.com
Eton Pharmaceuticals Rallies as Stock Approaches Key Resistance (ETON)Total Put Call - newsline.com
Eton Pharmaceuticals (ETON) Holds Steady Near Resistance With Modest GainDividend ETF - newsline.com
ETON Q1 2026 Earnings: EPS Misses Estimates Despite Narrow ProfitCore Business Growth - newsline.com
Possible Bearish Signals With Eton Pharmaceuticals Insiders Disposing Stock - simplywall.st
ETON: Aggressively scaling rare disease portfolio with strong sales, margin growth, and patient focus - TradingView
[144] Eton Pharmaceuticals, Inc. SEC Filing - Stock Titan
Eton Pharmaceuticals (ETON) CFO reports 37,000 employee stock options - Stock Titan
Eton Pharmaceuticals CEO Sean Brynjelsen sells $3.83 million in stock - Investing.com India
Eton Pharmaceuticals Inc (ETON) Shares Fall 4.3% -- What GF Scor - GuruFocus
Eton Pharmaceuticals CEO Sean Brynjelsen sells $3.83 million in stock By Investing.com - Investing.com South Africa
(ETON) Volatility Zones as Tactical Triggers - Stock Traders Daily
Eton Pharmaceuticals (ETON) CEO reports open-market sale of 120,000 shares - Stock Titan
120,000 ETON shares proposed for sale by affiliate (ETON) - Stock Titan
Eton Pharmaceuticals, Inc. $ETON Shares Sold by UBS Group AG - MarketBeat
Eton Pharmaceuticals Insider Sold Shares Worth $3,229,923, According to a Recent SEC Filing - Moomoo
Eton Pharmaceuticals CBO David Krempa sells $3.2m in stock By Investing.com - Investing.com Canada
Eton (ETON) CBO sells 100,000 shares after exercising 87,794 options - Stock Titan
Eton Pharmaceuticals (ETON) soars 6.7%: Is further upside left in the stock? - MSN
ETON SEC FilingsEton Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
H.C. Wainwright Remains Bullish on Eton Pharmaceuticals’ (ETON) Growth Strategy - Insider Monkey
Eton Pharmaceuticals Inc (ETON) Shares Fall 6.9% -- GF Value Says Still Overvalued - GuruFocus
ETON (Nasdaq) Rule 144 shows RSUs and Options grants dated 2024–2026 - Stock Titan
5 Oversold Growth Stocks to Invest In Now - Insider Monkey
H.C. Wainwright reiterates Eton Pharmaceuticals stock rating at buy By Investing.com - Investing.com Canada
Earnings call transcript: Eton Pharmaceuticals Q1 2026 shows mixed results By Investing.com - Investing.com Nigeria
Earnings call transcript: Eton Pharmaceuticals Q1 2026 shows mixed results - Investing.com
Eton Pharmaceuticals acquires U.S. rights to leishmaniasis drug By Investing.com - Investing.com India
Eton Pharmaceuticals, Inc.Common Stock (NQ: ETON - The Chronicle-Journal
Eton Pharmaceuticals acquires U.S. rights to leishmaniasis drug - Investing.com
Eton Pharmaceuticals Obtains US Commercialization Rights to Impavido - Moomoo
Eton (NASDAQ: ETON) licenses U.S. IMPAVIDO rights in rare disease push - Stock Titan
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine) - The Manila Times
Eton Pharmaceuticals Announces U.S. Commercialization Rights for IMPAVIDO®, First FDA-Approved Oral Therapy for Leishmaniasis - Quiver Quantitative
Eton Pharmaceuticals Expands Rare Disease Portfolio Through - GlobeNewswire
Price-Driven Insight from (ETON) for Rule-Based Strategy - Stock Traders Daily
H.C. Wainwright raises Eton Pharmaceuticals stock price target to $57 By Investing.com - Investing.com Canada
Eton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next - Yahoo Finance
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q1 2026 Earnings Call Transcript - Insider Monkey
2.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):